Lv12
86 积分 2025-08-12 加入
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
8小时前
已完结
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial
1天前
已完结
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
4天前
已完结
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
4天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
5天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
5天前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
8天前
已完结
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
29天前
已完结
Recent advances in Alzheimer's disease: From molecular mechanisms to therapeutic strategies
1个月前
已完结
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA
1个月前
已完结
皖公网安备34019202002308
